Source:http://linkedlifedata.com/resource/pubmed/id/18027211
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2007-11-20
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1054-3406
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1013-4; discussion 1029-32
|
pubmed:meshHeading | |
pubmed:year |
2007
|
pubmed:articleTitle |
Discussion of the "White Paper of the PhRMA PISC Working Group on adaptive dose-ranging designs".
|
pubmed:affiliation |
Research Statistics Unit, GlaxoSmithKline Pharmaceuticals. Sergei.2.Leonov@gsk.com
|
pubmed:publicationType |
Journal Article,
Comment
|